Diabetic ketoacidosis in patients with type 2 diabetes treated with sodium glucose co‐transporter 2 inhibitors versus other antihyperglycemic agents: An observational study of four US administrative claims databases

To compare the incidence of diabetic ketoacidosis (DKA) among patients with type 2 diabetes mellitus (T2DM) who were new users of sodium glucose co‐transporter 2 inhibitors (SGLT2i) versus other classes of antihyperglycemic agents (AHAs).

[1]  Declare–Timi Investigators.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019 .

[2]  Deepak L. Bhatt,et al.  Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes , 2019, The New England journal of medicine.

[3]  K. Lee,et al.  Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study , 2018, Diabetes, obesity & metabolism.

[4]  D. Bell.  RE: DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES ON SGLT-2 INHIBITORS: AN ONGOING CONCERN. , 2018, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[5]  S. Jabbour,et al.  Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials , 2017, Diabetes, obesity & metabolism.

[6]  M. Monami,et al.  Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials. , 2017, Diabetes research and clinical practice.

[7]  K. Brodovicz,et al.  Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review , 2017, BMJ Open.

[8]  S. Kaspers,et al.  Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I–III Clinical Trials , 2017, Advances in Therapy.

[9]  K. Mahaffey,et al.  Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.

[10]  S. Schneeweiss,et al.  Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. , 2017, The New England journal of medicine.

[11]  Martijn J Schuemie,et al.  Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. , 2017, Diabetes research and clinical practice.

[12]  R. Crowley,et al.  DIABETIC KETOACIDOSIS IN PATIENTS WITH TYPE 2 DIABETES RECENTLY COMMENCED ON SGLT-2 INHIBITORS: AN ONGOING CONCERN. , 2017, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[13]  M. Ridderstråle,et al.  Incidence of Ketoacidosis in the Danish Type 2 Diabetes Population Before and After Introduction of Sodium–Glucose Cotransporter 2 Inhibitors—A Nationwide, Retrospective Cohort Study, 1995–2014 , 2017, Diabetes Care.

[14]  S. Zhai,et al.  Effect of Sodium–Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials , 2016, Diabetes Care.

[15]  A. Kong,et al.  Practical considerations for the use of sodium–glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes , 2016, Current medical research and opinion.

[16]  B. Zinman,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.

[17]  G. Meininger,et al.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program , 2015, Diabetes Care.

[18]  D. Russell-Jones,et al.  SGLT inhibition and euglycaemic diabetic ketoacidosis. , 2015, The lancet. Diabetes & endocrinology.

[19]  Vivienne J. Zhu,et al.  Feasibility and utility of applications of the common data model to multiple, disparate observational health databases , 2015, J. Am. Medical Informatics Assoc..

[20]  E. Gosmanova,et al.  Management of adult diabetic ketoacidosis , 2014, Diabetes, metabolic syndrome and obesity : targets and therapy.

[21]  William DuMouchel,et al.  Interpreting observational studies: why empirical calibration is needed to correct p-values , 2013, Statistics in medicine.

[22]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[23]  Patrick B. Ryan,et al.  Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model , 2012, TOMC.

[24]  Tim Nolan,et al.  International Diabetes Federation. , 2013, Diabetes research and clinical practice.

[25]  Abhi Shelat,et al.  One‐to‐many propensity score matching in cohort studies , 2012, Pharmacoepidemiology and drug safety.

[26]  P. Austin,et al.  Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies , 2010, Pharmaceutical statistics.

[27]  J. N. Fisher,et al.  Hyperglycemic Crises in Adult Patients With Diabetes , 2009, Diabetes Care.

[28]  J. Eriksson,et al.  Ketoacidosis occurs in both Type 1 and Type 2 diabetes— a population‐based study from Northern Sweden , 2008, Diabetic medicine : a journal of the British Diabetic Association.

[29]  David Madigan,et al.  Large-Scale Bayesian Logistic Regression for Text Categorization , 2007, Technometrics.

[30]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .

[31]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.